Cargando…
A Unique Topoisomerase II Inhibitor with Dose-Affected Anticancer Mechanisms and Less Cardiotoxicity
Type II DNA topoisomerase (topo II) is an essential nuclear enzyme and a well-validated anticancer drug target. Previously, we have carried out several rounds of structural optimizations on our in-house topo II inhibitor E17, which was shown to have superior anticancer activity and less risk of mult...
Autores principales: | Li, Zhi-Ying, Xu, Guang-Sen, Li, Xun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621772/ https://www.ncbi.nlm.nih.gov/pubmed/34831359 http://dx.doi.org/10.3390/cells10113138 |
Ejemplares similares
-
Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021) -
A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents
por: Okoro, Cosmas O., et al.
Publicado: (2023) -
On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs
por: Wu, Chyuan-Chuan, et al.
Publicado: (2013) -
Mechanisms regulating resistance to inhibitors of topoisomerase II
por: Ganapathi, Ram N., et al.
Publicado: (2013) -
Design, Synthesis, and Anticancer Evaluation of Novel Indole Derivatives of Ursolic Acid as Potential Topoisomerase II Inhibitors
por: Li, A-Liang, et al.
Publicado: (2020)